On the Record · PharMerica

PharMerica acquisitions, on the record

The businesses PharMerica bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.

Deals its annual reports describe

Business	Deal	When	Value
institutional pharmacy businesses Word for word“Since its formation in 2006, the Corporation has acquired 16 institutional pharmacy businesses, two specialty infusion services business and one specialty oncology pharmacy.” 10-K for 2014	acquisition	Since its formation in 2006	—
Amerita Word for word“The change in the revenue by payer type, as a percent of total revenue, over the three year period is a result of the 2012 acquisition of Amerita and the 2013 acquisition of Onco, both of which are more heavily weighted to insured and Medicare payer sources.” 10-K for 2014	acquisition	2012	—
Onco Word for word“The change in the revenue by payer type, as a percent of total revenue, over the three year period is a result of the 2012 acquisition of Amerita and the 2013 acquisition of Onco, both of which are more heavily weighted to insured and Medicare payer sources.” 10-K for 2014	acquisition	2013	—
Amerita Inc. ("Amerita") Word for word“The decline was partially offset by the acquisition of Amerita Inc. ("Amerita") in the fourth quarter of 2012.” 10-K for 2014	acquisition	fourth quarter of 2012	—
OncoMed Specialty, LLC ("Onco") Word for word“While gross profit margin was adversely impacted by lower margins in the Corporation’s Onco oncology business, the gross profit per prescription dispensed is favorably impacted by the acquisition of Onco on December 6, 2013.” 10-K for 2014	acquisition	December 6, 2013	—
five acquisitions of long-term care businesses (the "2013 Acquisitions") Word for word“Revenues increased $136.6 million for the year ended December 31, 2014 compared to the year ended December 31, 2013 as a result of the inclusion of a full year of revenues from the five acquisitions of long-term care businesses in 2013 (the “2013 Acquisitions”) and the acquisition of OncoMed Specialty, LLC (“Onco”).” 10-K for 2014	acquisition	2013	—
four long-term care businesses and one infusion business (the "2014 Acquisitions") Word for word“in addition, revenues increased as a result of the acquisitions of four long-term care businesses and one infusion business (collectively, the “2014 Acquisitions”).” 10-K for 2014	acquisition	2014	—
businesses acquired in 2014 Word for word“The increase in cash used in investing activities is primarily due to the five businesses the Corporation acquired in 2014, partially offset by a decrease in capital expenditures.” 10-K for 2014	acquisition	2014	—
Onco (OncoMed Specialty, LLC) Word for word“Revenues increased $136.6 million for the year ended December 31, 2014 compared to the year ended December 31, 2013 as a result of the inclusion of a full year of revenues from the five acquisitions of long-term care businesses in 2013 (the "2013 Acquisitions") and the acquisition of OncoMed Specialty, LLC ("Onco")” 10-K for 2015	acquisition	2013	—
five long-term care businesses (2013 Acquisitions) Word for word“Revenues increased $136.6 million for the year ended December 31, 2014 compared to the year ended December 31, 2013 as a result of the inclusion of a full year of revenues from the five acquisitions of long-term care businesses in 2013 (the "2013 Acquisitions") and the acquisition of OncoMed Specialty, LLC ("Onco")” 10-K for 2015	acquisition	2013	—
2015 Acquisitions (unnamed businesses) Word for word“The increase was related to costs associated with the 2014 Acquisitions and 2015 Acquisitions.” 10-K for 2015	acquisition	2015	—

As filedReported in the company's financial data (XBRL), each linked to its filing
Fiscal year ended	Cash paid for acquisitions (net of cash acquired)	Cash received from selling businesses	Goodwill from acquisitions
2016-12-31	$57.6 million	$0	$20.1 million

Deal filings since 2016

2017-12-07 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2017-08-03 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-12-15 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement

Read from PharMerica’s annual reports (10-K for 2016, 10-K for 2015, 10-K for 2014) and the financial data it files with the SEC, as of 2017-02-24. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.